{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:48:40Z","timestamp":1787021320386,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024075","name":"Region Syddanmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010306","name":"Direkt\u00f8r Kurt B\u00f8nnelycke og Hustru fru Grethe B\u00f8nnelyckes Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010346","name":"Else og Mogens Wedell Wedellsborgs Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009906","name":"Grosserer A.V. Lykfeldt og Hustrus Legat","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009906","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006356","name":"Syddansk Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Axillary lymph node dissection (ALND) is associated with considerable risk of arm morbidity. This study aimed to identify risk factors for additional disease found at ALND in patients with a diagnosis of clinically node-negative (cN0) breast cancer who had sentinel lymph node (SLN) metastasis after neoadjuvant chemotherapy (NACT) as a help to identify patients for whom ALND may be safely omitted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective national cohort study analyzed Danish patients with a diagnosis of cT1-3 breast cancer and cN0 disease from October 2016 to November 2022 but a positive SLN biopsy after NACT. Uni- and multivariable logistic regression analyses with stepwise backward elimination were performed to identify factors predictive of additional axillary disease at ALND.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study identified 346 patients eligible for analyses. Additional disease at ALND was found in 111 patients (32 %), but only 11 % of those with isolated tumor cells in the SLNs had additional axillary disease. It was respectively 22 % and 42 % for micro- and macrometastases. The final multivariable model identified the size of the metastatic deposit in the SLN, the ratio of positive SLNs, extracapsular extension, multifocality, and clinical T-stage as significant predictors of additional axillary disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with isolated tumor cells in the sentinel nodes after NACT have a limited risk of additional axillary disease at ALND. However, other factors influence the probability and may be considered in an individualized approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18045-7","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T17:19:10Z","timestamp":1755710350000},"page":"9807-9816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Additional Axillary Disease After Neoadjuvant Chemotherapy for Patients with Clinically Node-Negative but Sentinel Node-Positive Disease"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8662-0515","authenticated-orcid":false,"given":"S.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. F.","family":"Tvedskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bechmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Tramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-B.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. B.","family":"Rahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D.","family":"Lautrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"18045_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","volume":"47","author":"S Kahler-Ribeiro-Fontana","year":"2021","unstructured":"Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single-institution ten-year follow-up. Eur J Surg Oncol. 2021;47:804\u201312. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.014.","journal-title":"Eur J Surg Oncol."},{"key":"18045_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/SLA.0b013e3181b8fd5e","volume":"250","author":"KK Hunt","year":"2009","unstructured":"Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558\u201366. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b8fd5e.","journal-title":"Ann Surg."},{"key":"18045_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","volume":"173","author":"JM Classe","year":"2019","unstructured":"Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173:343\u201352. https:\/\/doi.org\/10.1007\/s10549-018-5004-7.","journal-title":"Breast Cancer Res Treat."},{"key":"18045_CR4","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1016\/j.ejca.2009.08.001","volume":"45","author":"CHM van Deurzen","year":"2009","unstructured":"van Deurzen CHM, Vriens BEPJ, Tjan-Heijnen VCG, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2009.08.001.","journal-title":"Eur J Cancer."},{"key":"18045_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/jrms.JRMS_127_18","volume":"24","author":"A Shirzadi","year":"2019","unstructured":"Shirzadi A, Mahmoodzadeh H, Qorbani M. Assessment of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer in two subgroups: initially node-negative and node-positive converted to node-negative: a systemic review and meta-analysis. J Res Med Sci. 2019;24:18. https:\/\/doi.org\/10.4103\/jrms.JRMS_127_18.","journal-title":"J Res Med Sci."},{"key":"18045_CR6","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1200\/JCO.2005.05.188","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2005;23:2694\u2013702. https:\/\/doi.org\/10.1200\/JCO.2005.05.188.","journal-title":"J Clin Oncol."},{"key":"18045_CR7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","volume":"14","author":"T DiSipio","year":"2013","unstructured":"DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(13)70076-7.","journal-title":"Lancet Oncol."},{"key":"18045_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamasurg.2019.1742","volume":"154","author":"JM Armer","year":"2019","unstructured":"Armer JM, Ballman KV, McCall L, et al. Factors associated with lymphedema in women with node-positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection. JAMA Surg. 2019;154:800\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2019.1742.","journal-title":"JAMA Surg."},{"key":"18045_CR9","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1245\/s10434-017-5960-x","volume":"24","author":"TT Nguyen","year":"2017","unstructured":"Nguyen TT, Hoskin TL, Habermann EB, Cheville AL, Boughey JC. Breast cancer-related lymphedema risk is related to multidisciplinary treatment and not surgery alone: results from a large cohort study. Ann Surg Oncol. 2017;24:2972\u201380. https:\/\/doi.org\/10.1245\/s10434-017-5960-x.","journal-title":"Ann Surg Oncol."},{"key":"18045_CR10","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.20.00459","volume":"38","author":"GE Naoum","year":"2020","unstructured":"Naoum GE, Roberts S, Brunelle CL, et al. Quantifying the impact of axillary surgery and nodal irradiation on breast cancer-related lymphedema and local tumor control: long-term results from a prospective screening trial. J Clin Oncol. 2020;38:3430\u20138. https:\/\/doi.org\/10.1200\/JCO.20.00459.","journal-title":"J Clin Oncol."},{"key":"18045_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/bjs\/znad215","volume":"110","author":"C Tinterri","year":"2023","unstructured":"Tinterri C, Canavese G, Gatzemeier W, et al. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment. Br J Surg. 2023;110:1143\u201352. https:\/\/doi.org\/10.1093\/bjs\/znad215.","journal-title":"Br J Surg."},{"key":"18045_CR12","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1002\/cam4.5257","volume":"12","author":"G Houvenaeghel","year":"2023","unstructured":"Houvenaeghel G, de Nonneville A, Chopin N, et al. The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases. Cancer Med. 2023;12:4023\u201332. https:\/\/doi.org\/10.1002\/cam4.5257.","journal-title":"Cancer Med."},{"key":"18045_CR13","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","volume":"19","author":"V Galimberti","year":"2018","unstructured":"Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23\u201301): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1385\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30380-2.","journal-title":"Lancet Oncol."},{"key":"18045_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"JAMA."},{"key":"18045_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Filtenborg Tvedskov T, Ryd\u00e9n L, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Eng J Med. 2024;390:1163\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2313487.","journal-title":"N Eng J Med."},{"key":"18045_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment, and follow-up. Ann Oncol. 2024;35:159\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","journal-title":"Ann Oncol."},{"key":"18045_CR17","unstructured":"Rashmi Kumar N, Schonfeld R, Gradishar WJ, et al. NCCN Guidelines Version 4.2024 Breast Cancer. Retrieved 2024 at https:\/\/www.nccn.org\/."},{"key":"18045_CR18","unstructured":"DMCG kliniske retningsliner for brystkr\u00e6ft (DBCG). Retrieved 25 April 2025 at https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/brystcancer\/."},{"key":"18045_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2024.102062","volume":"54","author":"S Arag\u00f3n-S\u00e1nchez","year":"2024","unstructured":"Arag\u00f3n-S\u00e1nchez S, S\u00e1nchez-Bayona R, L\u00f3pez-Mar\u00edn L, et al. De-escalating axillary management after neoadjuvant chemotherapy in breast cancer: the ratio of positive sentinel lymph nodes matters. Surg Oncol. 2024;54:102062. https:\/\/doi.org\/10.1016\/j.suronc.2024.102062.","journal-title":"Surg Oncol."},{"key":"18045_CR20","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1177\/00031348241248813","volume":"90","author":"NC Johnson","year":"2024","unstructured":"Johnson NC, Kornfeld H, Gonzalez L, et al. Factors associated with additional axillary disease in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy for breast cancer. Am Surg. 2024;90:2614\u201321. https:\/\/doi.org\/10.1177\/00031348241248813.","journal-title":"Am Surg."},{"key":"18045_CR21","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1245\/s10434-022-12064-4","volume":"29","author":"SB Sanders","year":"2022","unstructured":"Sanders SB, Hoskin TL, Stafford AP, Boughey JC. Factors influencing non-sentinel lymph node involvement in patients with positive sentinel lymph node(s) after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2022;29:7769\u201378. https:\/\/doi.org\/10.1245\/s10434-022-12064-4.","journal-title":"Ann Surg Oncol."},{"key":"18045_CR22","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1245\/s10434-021-09910-2","volume":"28","author":"TA Moo","year":"2021","unstructured":"Moo TA, Pawloski KR, Flynn J, et al. Is residual nodal disease at axillary dissection associated with tumor subtype in patients with low-volume sentinel node metastasis after neoadjuvant chemotherapy? Ann Surg Oncol. 2021;28:6044\u201350. https:\/\/doi.org\/10.1245\/s10434-021-09910-2.","journal-title":"Ann Surg Oncol."},{"key":"18045_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01052","author":"G Montagna","year":"2024","unstructured":"Montagna G, Laws A, Ferrucci M, et al. Nodal Burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05\/ICARO study. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.24.01052.","journal-title":"J Clin Oncol."},{"key":"18045_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.radonc.2021.08.013","volume":"163","author":"MC Leonardi","year":"2021","unstructured":"Leonardi MC, Arrobbio C, Gandini S, et al. Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. Radiother Oncol. 2021;163:128\u201335. https:\/\/doi.org\/10.1016\/j.radonc.2021.08.013.","journal-title":"Radiother Oncol."},{"key":"18045_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12957-024-03537-9","volume":"22","author":"X Tang","year":"2024","unstructured":"Tang X, Feng Y, Zhao W, Liu R, Chen N. Prediction of non-sentinel lymph node metastases in T1\u20132 sentinel lymph node-positive breast cancer patients undergoing mastectomy following neoadjuvant therapy. World J Surg Oncol. 2024;22:258. https:\/\/doi.org\/10.1186\/s12957-024-03537-9.","journal-title":"World J Surg Oncol."},{"key":"18045_CR26","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/cncr.23481","volume":"112","author":"JS Jeruss","year":"2008","unstructured":"Jeruss JS, Newman LA, Ayers GD, et al. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer. 2008;112:2646\u201354. https:\/\/doi.org\/10.1002\/cncr.23481.","journal-title":"Cancer."},{"key":"18045_CR27","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1245\/s10434-018-6578-3","volume":"25","author":"AU Barron","year":"2018","unstructured":"Barron AU, Hoskin TL, Boughey JC. Predicting non-sentinel lymph node metastases in patients with a positive sentinel lymph node after neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25:2867\u201374. https:\/\/doi.org\/10.1245\/s10434-018-6578-3.","journal-title":"Ann Surg Oncol."},{"key":"18045_CR28","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1245\/s10434-023-13231-x","volume":"30","author":"I Cebrecos","year":"2023","unstructured":"Cebrecos I, Mension E, Alonso I, et al. Nonsentinel axillary lymph node status in clinically node-negative early breast cancer after primary systemic therapy and positive sentinel lymph node: a predictive model proposal. Ann Surg Oncol. 2023;30:4657\u201368. https:\/\/doi.org\/10.1245\/s10434-023-13231-x.","journal-title":"Ann Surg Oncol."},{"key":"18045_CR29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16382-7","author":"A So","year":"2024","unstructured":"So A, Yi M, Simons JM, et al. Significance of residual nodal disease in clinically node-negative breast cancer after neoadjuvant chemotherapy. Ann Surg Oncol. 2024. https:\/\/doi.org\/10.1245\/s10434-024-16382-7.","journal-title":"Ann Surg Oncol"},{"key":"18045_CR30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2147\/CLEP.S99457","volume":"8","author":"P Christiansen","year":"2016","unstructured":"Christiansen P, Ejlertsen B, Jensen MB, Mouridsen H. Danish breast cancer cooperative group. Clin Epidemiol. 2016;8:445\u20139. https:\/\/doi.org\/10.2147\/CLEP.S99457.","journal-title":"Clin Epidemiol."},{"issue":"7 Suppl","key":"18045_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1403494810393563","volume":"39","author":"B Bjerregaard","year":"2011","unstructured":"Bjerregaard B, Larsen OB. The Danish pathology register. Scand J Public Health. 2011;39(7 Suppl):72\u20134. https:\/\/doi.org\/10.1177\/1403494810393563.","journal-title":"Scand J Public Health."},{"key":"18045_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","volume":"18","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18:800\u20134. https:\/\/doi.org\/10.1097\/EDE.0b013e3181577654.","journal-title":"Epidemiology."},{"key":"18045_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","volume":"147","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer American Society of clinical oncology-college of American Pathologists guideline update. Arch Pathol Lab Med. 2023;147:993\u20131000. https:\/\/doi.org\/10.5858\/arpa.2023-0950-SA.","journal-title":"Arch Pathol Lab Med."},{"key":"18045_CR34","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1245\/s10434-024-15354-1","volume":"31","author":"F Munck","year":"2024","unstructured":"Munck F, Jensen MB, Vejborg I, et al. Residual axillary metastases in node-positive breast cancer patients after neoadjuvant treatment: a register-based study. Ann Surg Oncol. 2024;31:5157\u201367. https:\/\/doi.org\/10.1245\/s10434-024-15354-1.","journal-title":"Ann Surg Oncol."},{"key":"18045_CR35","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(22)00482-X","volume":"23","author":"SR de Wild","year":"2022","unstructured":"de Wild SR, de Munck L, Simons JM, et al. De-escalation of radiotherapy after primary chemotherapy in cT1\u20132N1 breast cancer (RAPCHEM; BOOG 2010\u201303): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol. 2022;23:1201\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(22)00482-X.","journal-title":"Lancet Oncol."},{"key":"18045_CR36","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1200\/JCO.23.00435","volume":"41","author":"JK Litton","year":"2023","unstructured":"Litton JK, Regan MM, Pusztai L, et al. Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP. J Clin Oncol. 2023;41:4433\u201342. https:\/\/doi.org\/10.1200\/JCO.23.00435.","journal-title":"J Clin Oncol."},{"key":"18045_CR37","unstructured":"A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. Retrieved 25 April 2025 at https:\/\/www.clinicaltrials.gov\/study\/NCT01872975."},{"key":"18045_CR38","unstructured":"Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS): A Multicenter Randomized Phase III Trial (OPBC-03\/ SAKK 23\/16 \/IBCSG 57-18\/ABCSG-53\/GBG-101). Retrieved 25 April 2025 at https:\/\/clinicaltrials.gov\/study\/NCT03513614."},{"key":"18045_CR39","unstructured":"A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1\u20133 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy. Retrieved 25 April 2025 at https:\/\/clinicaltrials.gov\/study\/NCT01901094."},{"key":"18045_CR40","doi-asserted-by":"publisher","first-page":"02","DOI":"10.1158\/1538-7445.SABCS23-GS02-07","volume":"84","author":"E Mamounas","year":"2024","unstructured":"Mamounas E, Bandos H, White J, et al. Abstract GS02-07: loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology\/NSABP B-51\/RTOG 1304. Cancer Res. 2024;84:02\u20137. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-GS02-07.","journal-title":"Cancer Res"},{"key":"18045_CR41","doi-asserted-by":"publisher","unstructured":"Garcia-Tejedor A, Ortega-Exposito C, Salinas S, et al. Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial). Front Oncol. 2023;13. https:\/\/doi.org\/10.3389\/fonc.2023.1184021.","DOI":"10.3389\/fonc.2023.1184021"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18045-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18045-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18045-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:18:27Z","timestamp":1762352307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18045-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":41,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["18045"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18045-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.-B. Jensen reports financial interests as a member of an advisory board for Novartis. T. Bechmann reports financial interests as a member of an advisory board for AstraZeneca. T. Tramm reports financial interests as a member of an advisory board for AstraZeneca and has received honoraria for lectures from Pfizer. All interests are unrelated to the submitted work. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The processing of personal data was reported to and approved by the Region of Southern Denmark and listed in the internal record (21\/54354 and 21\/50412) cf. Art 30 of The EU General Data Protection Regulation. According to Danish law, ethical approval from the Ethical Committee is not required for this type of register-based study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}